KalVista Pharmaceuticals (KALV) Preferred Stock Liabilities (2014 - 2015)
KalVista Pharmaceuticals recorded quarterly Preferred Stock Liabilities of $39.6 million in Q1 2015, up 420.82% quarter-over-quarter from $7.6 million in Q4 2014.
KalVista Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $39.6 million for Q1 2015.
- In Q1 2015, Preferred Stock Liabilities changed N/A year-over-year to $39.6 million; the TTM figure through Mar 2015 stood at $39.6 million (changed N/A YoY), while the FY2016 annual figure was $58.6 million, up 128.88% from the prior year.
- Preferred Stock Liabilities came in at $39.6 million for Q1 2015 at KalVista Pharmaceuticals, up from $7.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $39.6 million in Q1 2015 to a low of $7.6 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 39.56 Mn |
| Dec 31, 2014 | 7.60 Mn |